Comparative histological study of hepatoprotective efficacy of Vitamin C and Platelet-Rich Plasma Against Carboplatin-Induced Liver Damage in Male Albino Rats
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 Dey 2026
,
Page 1-8
https://doi.org/10.22037/ijmtfm.v16.52804
Abstract
Background: Carboplatin is an effective platinum-based chemotherapeutic agent; however, its use may be complicated by hepatotoxicity. Vitamin C (VC) and platelet-rich plasma (PRP) possess antioxidant and regenerative properties that may mitigate hepatic injury. To compare the individual and combined effects of vitamin C and PRP on carboplatin-induced histopathological liver injury in male albino rats.
Methods: Thirty adult male rats were split into five groups (6 per group): control; carboplatin alone; carboplatin plus vitamin C; carboplatin plus PRP; and carboplatin plus vitamin C and PRP. Carboplatin was administered intraperitoneally (60 mg/kg) on day 1. Vitamin C (100 mg/kg, intraperitoneally) was administered daily on days 0–7, and PRP (150 μL/rat, subcutaneously) was administered on days 0, 2, 4, and 6. PRP was prepared using double centrifugation. Hematoxylin and eosin-stained liver sections were examined microscopically.
Results: Carboplatin caused marked disruption of hepatic cords, severe hepatocellular swelling and necrosis, and central venous alterations in the rat liver. Vitamin C or PRP treatment individually largely preserved normal lobular cytoarchitecture, with appearances comparable to that of the controls. Combined treatment also produced predominantly normal architecture; however, focal mild zonal or vacuolar degeneration and hepatocellular necrosis persisted, indicating no superior protection.
Conclusion: Vitamin C and PRP attenuated carboplatin-induced hepatic histopathology in rats, whereas their combination provided incomplete protection without evident additive benefits. However, quantitative histological, biochemical, and dose-response studies are required before clinical translation.
- Vitamin C, Platelet-Rich plasma, Carboplatin, Chemical and drug-induced liver injury, Rats, Hepatoprotective, Chemotherapy
How to Cite
References
[1] Agrawal P, Jain M. The amelioration of side effects associated with chemotherapy. Curr Cancer Ther Rev. 2025;21:164–75. [DOI: 10.2174/0115733947274568231121173724]
[2] Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11:3461–74. [Link]
[3] Griesinger F, Korol EE, Kayaniyil S, Schuler M, Eberhardt WEE, Murtaza G, et al. Efficacy and safety of first-line carboplatin- versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2019;135:196–204. [DOI: 10.1016/j.lungcan.2019.07.010]
[4] Stevens SM, McClelland CM, Trusheim JE, Bhatt A, Savino PJ, Liu GT, et al. Carboplatin-associated cranial neuropathy. J Neuroophthalmol. 2018;42:302–5. [DOI: 10.1080/01658107.2017.1419367]
[5] Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol. 2015;308:G223–32. [DOI: 10.1152/ajpgi.00212.2014]
[6] Cao S, Wang C, Ma H, Yin R, Zhu M, Shen W, et al. Genome-wide association study on platinum-induced hepatotoxicity in non-small cell lung cancer patients. Sci Rep. 2015;5:11556. [DOI: 10.1038/srep11556]
[7] Das SK, Nerune SM, Das KK. Antioxidant therapy for hepatic diseases: a double-edged sword. J Basic Clin Physiol Pharmacol. 2024;35:7–14. [DOI: 10.1515/jbcpp-2023-0156]
[8] Abdulrazzaq AM, Badr M, Gammoh O, Abu-Rish EY, Salim S, Hjh M, et al. Hepatoprotective actions of ascorbic acid, alpha lipoic acid and silymarin or their combination against acetaminophen-induced hepatotoxicity in rats. Medicina. 2019;55:181. [DOI: 10.3390/medicina55050181]
[9] Okereke UO, Mbah A, Nwosu IC, et al. Investigating the protective effects of ascorbic acid against paracetamol-induced liver toxicity in Wistar rats. Asian J Res Med Pharm Sci. 2024;13:1–8. [DOI: 10.9734/ajrimps/2024/v13i4269]
[10] Wu WS, Chen LR, Chen KH. Platelet-rich plasma (PRP): molecular mechanisms, actions and clinical applications in human body. Int J Mol Sci. 2025;26:10804. [DOI: 10.3390/ijms262110804]
[11] Pineda-Cortel MR, Suarez C, Cabrera JT, et al. Complexity of platelet-rich plasma: mechanism of action, growth factor utilization and variation in preparation. Plasmatology. 2024;18:26348535241277625. [DOI: 10.1177/26348535241277625]
[12] Ballesta FJG, Vásquez LNA, Borbón JR, et al. Management of platelet-rich plasma and stem cells versus conventional treatments in musculoskeletal injury repair: a systematic review. J Musculoskelet Surg Res. 2025;9:1–9. [DOI: 10.25259/JMSR_402_2025]
[13] Suvarna, SK, Layton C, Bancroft JD. Theory and practice of histological techniqueseighth. UK. Elsevier Health Sci. 2019;8:126-79. [Link]
[14] Hoofnagle JH, Björnsson ES. Drug-induced liver injury: types and phenotypes. N Engl J Med. 2019;381:264–73. [DOI: 10.1056/NEJMra1816149]
[15] Jaeschke H. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65:166–76. [DOI: 10.1093/toxsci/65.2.166]
[16] Kim SW, Paek J, Nam EJ, et al. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2010;152:195–9. [DOI: 10.1016/j.ejogrb.2010.05.033]
[17] Miyagi Y, Fujiwara K, Kigawa J, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy: a comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005;99:591–6. [DOI: 10.1016/j.ygyno.2005.06.055]
[18] Adikwu E, Deo O. Hepatoprotective effect of vitamin C (ascorbic acid). Pharmacol Pharm. 2013;4:84–92. [DOI: 10.4236/pp.2013.41012]
[19] EL-Gendy KS, Aly NM, Mahmoud FH, et al. The role of vitamin C as antioxidant in protection of oxidative stress induced by imidacloprid. Food Chem Toxicol. 2010;48:215–21. [DOI: 10.1016/j.fct.2009.10.003]
[20] Awodele O, Akintonwa A, Osunkalu VO, et al. Modulatory activity of antioxidants against the toxicity of rifampicin in vivo. Rev Inst Med Trop São Paulo. 2010;52:43–6. [DOI: 10.1590/S0036-46652010000100007]
[21] Reddy AG, Soujanya S, Lakshman M, et al. Evaluation of the protective role of vitamin C in imidacloprid-induced hepatotoxicity in male albino rats. J Nat Sci Biol Med. 2013;4:63. [DOI: 10.4103/0976-9668.107262]
[22] Pavlovic V, Ciric M, Jovanovic V, et al. Platelet rich plasma: a short overview of certain bioactive components. Open Med. 2016;11:242–7. [DOI: 10.1515/med-2016-0048]
[23] Ohkohchi N, Murata S, Takahashi K. Platelet and liver regeneration. In: Davies J, editor. Tissue regeneration: from basic biology to clinical application. InTech; 2012. [DOI: 10.5772/25422]
[24] Gilgenkrantz H, Collin de l’Hortet A. New insights into liver regeneration. Clin Res Hepatol Gastroenterol. 2011;35:623–9. [DOI: 10.1016/j.clinre.2011.04.002]
[25] Takahashi K, Liang C, Oda T, Ohkohchi N. Platelet and liver regeneration after liver surgery. Surg Today. 2020 ;50(9):974-83. [DOI: 10.1007/s00595-019-01890-x]
[26] Timoshnikov VA, Kobzeva TV, Polyakov NE, et al. Redox interactions of vitamin C and iron: inhibition of the pro-oxidant activity by deferiprone. Int J Mol Sci. 2020;21:3967. [DOI: 10.3390/ijms21113967]
[27] Cao X, Yi Y, Ji M, et al. The dual role of vitamin C in cancer: from antioxidant prevention to prooxidant therapeutic applications. Front Med (Lausanne). 2025;12:1633447. [DOI: 10.3389/fmed.2025.1633447]
[28] Ranzato E, Martinotti S, Volante A, Burlando B. Platelet lysate promotes mesenchymal stem cell ROS production required for activation of cell migration. Cell Prolif. 2011;44(2):183–92. [DOI: 10.1111/j.1365-2184.2011.00744.x]
[29] Murphy S, Gardner FH. Effect of pH on platelet aggregation and the release reaction. Blood. 1975;46(2):209–18. [DOI: 10.1182/blood.V46.2.209.209]
- Abstract Viewed: 104 times
- PDF Downloaded: 50 times